Publications

Hayes Publications are available through the Hayes Knowledge Center, a portal to world-class research and unbiased analyses on the clinical, financial, and risk impacts of emerging, controversial, and disruptive healthcare technologies.

Every Hayes publication is developed by multidisciplinary teams of clinicians and scientists using rigorous methods grounded in internally recognized standards for systematic review and Health Technology Assessment. Learn more about these evidence resources and see sample titles below.

See below for some of our recent publications.

Zolgensma (Onasemnogene Abeparvovec-xioi) for Spinal Muscular Atrophy

Zolgensma (onasemnogene abeparvovec-xioi; formerly AVXS-101) is an adeno-associated virus vector-based gene therapy indicated for the treatment of pediatric patients < 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. Zolgensma is intended to replace the defective

Zolgensma (Onasemnogene Abeparvovec-xioi) for Spinal Muscular Atrophy

Zolgensma (onasemnogene abeparvovec-xioi; formerly AVXS-101) is an adeno-associated virus vector-based gene therapy indicated for the treatment of pediatric patients < 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. Zolgensma is intended to replace the defective

Proton Beam Therapy for Treatment of Head and Neck Cancer

Health Problem: Head and neck cancer (HNC) accounts for approximately 4% of all cancers in the United States, with an estimated 65,410 new HNC diagnoses during 2019 and an estimated 14,620 deaths from the disease. HNC can have a negative impact on a person’s quality of life by affecting basic functions such as swallowing, hearing, and speakin…

Inebilizumab for Neuromyelitis Optica Spectrum Disorder

Inebilizumab is an investigational anti-CD19 monoclonal antibody. It was developed in response to the unmet treatment needs of patients with neuromyelitis optica spectrum disorder (NMOSD), a rare and debilitating autoimmune demyelinating disease that primary affects the optic nerves and spinal cord. Inebilizumab is administered every 26 weeks by intravenous infusion.

Viaskin Epicutaneous Immunotherapy (EPIT) for Peanut Allergy

Viaskin Peanut is an epicutaneously delivered immunotherapy in development for the treatment of peanut allergy. The Viaskin patch contains antigen in dry form, which adheres to a central backing surrounded by an adhesive crown that secures the patch to the skin, creating an occlusive chamber. The patch is applied once daily. The Viaskin patch works by gradually exposing the p…

Beovu (Brolucizumab) for Neovascular Age-Related Macular Edema

Beovu is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD). Inhibition of the VEGF pathway is believed to impede the growth of neovascular lesions, resolve retinal edema, and improve vision in patients with neovascular AMD.

Beovu (Brolucizumab) for Neovascular Age-Related Macular Degeneration

Beovu is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD). Inhibition of the VEGF pathway is believed to impede the growth of neovascular lesions, resolve retinal edema, and improve vision in patients with neovascular AMD.

Microsurgery for Primary Prevention of Breast Cancer Related Lymphedema

Health Problem: Lymphedema refers to the swelling that occurs due to the accumulation of protein-rich fluids in tissue experiencing inadequate lymphatic drainage. One of the most common causes of secondary lymphedema are treatments for breast cancer, including axillary lymph node dissection, mastectomy, lumpectomy, and axillary radiation ther…

Percutaneous Bone-Anchored Hearing Aids

Health Problem: In the United States, it is estimated that 48 million adults have some type of hearing loss. Hearing loss can be broadly classified as sensorineural (inner ear), conductive (external and middle ear), or mixed.

Technology Description: This report evaluates the use of pe…